Sanofi and Regeneron are throwing an already-approved drug at COVID-19, testing Kevzara (sarilumab) in patients hospitalised with severe disease. The thinking behind this trial is similar to that ...

Sanofi’s next-generation rheumatoid arthritis drug Kevzara has been approved in Europe, giving a new option for patients who are intolerant to other treatments.

Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary ...